Potential for immune reconstitution through G-CSF treatment of HIV patients

Archivum Immunologiae et Therapiae Experimentalis

Volumn 50, Issue 2, 2002, Pages 111-120

  Von Aulock, Sonja ^a   Hartung, Thomas ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

AIDS; G CSF; HIV; Immune reconstitution

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOMODULATION; OPPORTUNISTIC INFECTION; REVIEW; TREATMENT PLANNING; VIRUS LOAD; VIRUS REPLICATION; AIDS RELATED COMPLEX; BIOLOGICAL MODEL; DRUG EFFECT; IMMUNOLOGY; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTOPENIA; MONOCYTE; NEUTROPENIA; NEUTROPHIL;

ADJUVANTS, IMMUNOLOGIC; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HIV INFECTIONS; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTES; LYMPHOPENIA; MODELS, IMMUNOLOGICAL; MONOCYTES; NEUTROPENIA; NEUTROPHILS; HUMANS;

EID: 0036266691     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. + T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: Results from a randomized, placebo-controlled trial
2. Immunological and virological changes in antiretroviral naive human immunodeficiency virus infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART
3. Effects of G-CSF on telomere lengths in PBMCs from human immunodeficiency virus-infected patients: Results from a randomized, placebo-controlled trial
4. T-cell mean telomere length changes in treatment naive HIV-infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART
5. Restoration of the immune system with anti-retroviral therapy
6. Granulocyte- and granulocyte-macrophage colony-stimulating factors enhance neutrophil cytotoxicity toward HIV-infected cells
7. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients
8. AIDS research. Cytokines move from the margins into the spotlight
9. + cell response against human immunodeficiency virus: Implications for long-term survival
10. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity
11. The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam
12. Cytokine-mediated induction of human immunodeficiency virus (HIV) expression and cell death in chronically infected U1 cells: Do tumor necrosis factor alpha and gamma interferon selectively kill HIV-infected cells?
13. Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma
14. Macrophages, cytokines, and HIV
15. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection
16. The Th1-Th2 hypothesis of HIV infection: New insights
17. + T cells
18. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils
19. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome
20. Cytokines in HIV infection
21. Individual cell analysis of the cytokine repertoire in human immunodeficiency virus-1-infected monocytes/macrophages by a combination of immunocytochemistry and in situ hybridization
22. Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus
23. + and AIDS T-cell subsets
24. Host factors and the pathogenesis of HIV-induced disease
25. Role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of patients with HIV infection
26. Clinical significance of neutrophil functional activity in HIV infection
27. Efficacy of recombinant granulocyte colony-stimulating factor in the long-term treatment of AIDS-related neutropenia
28. Neutrophils from AIDS patients treated with granulocyte colony-stimulating factor demonstrate enhanced killing of Mycobacterium avium
29. Apoptosis and the CD95 system in HIV disease: Impact of highly active anti-retroviral therapy (HAART)
30. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis
31. Selective loss of T cell functions in different stages of HIV infection. Early loss of anti-CD3-induced T cell proliferation followed by decreased anti-CD3-induced cytotoxic T lymphocyte generation in AIDS-related complex and AIDS
32. Effect of HIV infection on the frequency of cytokine-secreting cells in human peripheral blood
33. Synergistic stimulatory effects of tumour necrosis factor alpha and interferon gamma on replication of human immunodeficiency virus type 1 and on apoptosis of HIV-1-infected host cells
34. Immunomodulation by colony-stimulating factors
35. Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions
36. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers
37. Filgrastim restores interleukin-2 production in blood from patients with advanced human immunodeficiency virus infection
38. Role of granulocyte colony-stimulating factor in infection and inflammation
39. Growth factors G-CSF and GM-CSF: Clinical options
40. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice
41. Granulocyte colony-stimulating factor treatment in AIDS patients
42. Haematopoietic growth factors as supportive therapy in HIV-infected patients
43. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection
44. Effect of recombinant human granulocyte colony-stimulating factor on Pneumocystis carinii infection in nude mice
45. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection
46. Neutropenia is associated with bacteremia in patients infected with the human immunodeficiency virus
47. G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection
48. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients
49. Interleukin-2 and human immunodeficiency virus infection: Pathogenic mechanisms and potential for immunologic enhancement
50. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study
51. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy
52. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial
53. Dysregulation of cytokine expression in monocytes from HIV-positive individuals
54. Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice
55. Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome
56. + T cells from HIV-infected persons
57. Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia
58. Role of T cell derived cytokines in HIV infection
59. Rational reconstitution of the immune repertoire in AIDS with autologous, antigen-specific, in vitro-expanded CD4 lymphocytes
60. Lack of induction of granulocyte colony-stimulating factor in human immunodeficiency virus-seropositive individuals
61. Defective phagocyte functions in HIV patients
62. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine
63. Bacteremia in HIV-positive and AIDS patients: Incidence, species distribution, risk-factors, outcome, and influence of long-term prophylactic antibiotic treatment
64. The use of hematopoietic growth factors in treating HIV infection
65. Hematopoietic growth factors as adjuncts to antiretroviral therapy
66. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine
67. Clinical uses of hematopoietic growth hormones in HIV-related illnesses
68. Neutropenia and bacterial infection in acquired immunodeficiency syndrome
69. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors
70. Impairment of neutrophil bactericidal capacity in patients with AIDS
71. Blood monocyte and neutrophil functions in the acquired immune deficiency syndrome
72. Treatment with granulocyte colony-stimulating factor decreases the capacity of hematopoietic progenitor cells for generation of lymphocytes in human immunodeficiency virus-infected persons
73. The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals
74. Accelerated neutrophil apoptosis in the acquired immunodeficiency syndrome
75. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms
76. Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response
77. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils
78. Role of TH1/TH2 cytokines in HIV infection
79. T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects
80. Serum of healthy donors receiving granulocyte colony-stimulating factor induces T cell unresponsiveness
81. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men
82. + memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T-cell functional defects observed in infected individuals
83. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus
84. Increase in lymphocyte subsets following treatment of HIV-associated neutropenia with granulocyte colony-stimulating factor
85. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection
86. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1
87. Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study
88. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS
89. Intermittent G-CSF (filgrastim) treatment cannot induce lymphocytosis in volunteers
90. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: A phase I/II study